the definition of an NDI to the elements needed for a successful filing.

Understanding New Dietary Ingredients (NDIs)

According to the FDA, a “new dietary ingredient” is any dietary ingredient that was not marketed in the U.S. as a dietary supplement before October 15, 1994, or has not been present in the food supply as an article used for food in a form in which it is used as a dietary supplement. Therefore, any company wanting to market a dietary supplement containing an NDI must submit a notification to the FDA.

Before preparing the safety dossier, it is essential to understand what constitutes an NDI. An ingredient may be considered “new” for several reasons:

• The ingredient has not been present in the food supply in a form used as a dietary supplement.
• The ingredient has undergone significant changes to its composition or processing.
• The structural characteristics of the ingredient are novel or unique.

The FDA’s expectations for the safety of these ingredients are clear. Generally, the safety of a new dietary ingredient notification safety dossier must demonstrate that an NDI is “reasonably expected to be safe” when consumed under the conditions of normal use.

Key Components of a New Dietary Ingredient Notification Safety Dossier

Building a safety dossier that meets FDA expectations entails compiling various types of information that substantiate the safety of the NDI. Below are the critical components that must be included in an NDI filing:

1. Identity of the New Dietary Ingredient

The first aspect focuses on thoroughly describing the identity of the NDI. This includes:

• The chemical name and common name.
• The source of the NDI (e.g., plant, mineral, or animal).
• The extraction and processing methods applied.
• The composition and specifications, including purity levels, in relation to other materials used in dietary supplements.

2. History of Use

Establishing a history of use is important for demonstrating safety. This data can include:

• The extent of prior consumption of the NDI as a food ingredient or dietary supplement.
• Safe consumption levels based on historical usage.
• Any available publications or studies that support its safety and historical usage.

Documenting the history of use can also provide contextual data that supports the rationale for the NDI’s inclusion in dietary supplements, which can be beneficial in the review process.

3. Toxicology Data

Mandatory toxicology data must be presented to support the safety of the NDI. This analysis should include:

• Acute toxicity studies that assess immediate health risks.
• Subchronic and chronic toxicity studies to understand the cumulative effects over time.
• Reproductive and developmental toxicity studies to assess impacts on reproductive health and development.
• Genotoxicity studies to determine if the substance poses a risk to DNA and cellular integrity.

The compilation of toxicology data should encompass data from reputable sources, laboratory studies, or historical safety data from similar dietary ingredients. It is advisable to follow GLP standards when conducting these studies to reassure regulatory authorities of their reliability.

4. Anticipated Conditions of Use

Describing how the NDI is intended to be used is crucial for understanding its safety profile. The following regarding anticipated conditions must be addressed:

• Manner of preparation (e.g., extracts, isolates, fermented).
• General consumption scenarios (e.g., single ingredient vs. multi-ingredient products).
• Daily intake levels and serving sizes.
• Target populations (e.g., general population, specific demographic groups such as pregnant women).

Providing details about the anticipated conditions of use allows the FDA to assess safety based on how the product will be consumed in the real world, enabling an informed review of your NDI safety dossier.

Documenting Your Safety Dossier

With the elements compiled, structuring your safety dossier in a clear and organized manner is paramount. Below is a suggested organization for the dossier:

• Cover Letter: An introduction explaining the purpose of the submission and highlighting key details such as the name of the NDI, the contacted parties, and a summary of the history of use.
• Table of Contents: A well-structured outline that facilitates easy navigation.
• Identity of the Ingredient: A detailed description of the NDI, including any known synonyms, composition, and specifications.
• History of Use Documentation: All relevant articles, studies, and data supporting the historical use claim.
• Toxicology Data Section: This should include all experiments conducted, methodologies used, results, and analyses of the data leading to the conclusions on safety.
• Conditions of Use Section: A clear description of expected consumer uses and intake levels.
• References Section: A comprehensive list of studies, articles, and resources cited in the dossier.

Submission Process for the NDI Safety Dossier

Once your safety dossier is complete, it can be submitted to the FDA for review. The submission process entails:

• Filing Type: The NDI notification is typically a written document that can be mailed or submitted electronically, depending on any guidelines provided by the FDA.
• FDA Communication: After submission, the FDA may provide communication for additional information or clarifications, which may be required before a final determination is made regarding the safety of your NDI.
• Response Time: Generally, the FDA aims to respond to NDI notifications within 75 days. Being transparent and providing complete documentation can facilitate timely responses.

It’s essential to keep abreast of any developments or changes in FDA policies regarding NDIs, as regulatory requirements may evolve.

Best Practices for NDI Filing

To ensure a successful outcome in the FDA’s review process, the following best practices can be employed during the preparation and submission of your new dietary ingredient notification safety dossier:

• Thorough Research: Conduct extensive literature reviews to substantiate the safety and history of use of your NDI.
• Consultation: Engage with toxicologists or regulatory affairs professionals to assist in the safety assessments and documentation.
• Quality Assurance: Ensure that the data is reliable and the methods used in studies are in conformity with relevant GLP standards.
• Stay Updated: Attend seminars and review guidance documents released by the FDA, especially when new guidance for NDIs is announced.

Conclusion

Building a new dietary ingredient notification safety dossier that meets FDA expectations requires meticulous planning, thorough documentation, and a comprehensive understanding of regulated environments. The safety dossier must convincingly demonstrate the identity, history of use, and safety through toxicology data and anticipated conditions of use for the new dietary ingredient. With adherence to these guidelines, regulatory professionals can support their company’s compliance efforts and help facilitate the introduction of new dietary ingredients safely into the marketplace.

For further information on NDI regulations, the FDA provides detailed guidelines in its Dietary Supplements page.